Currently, only four acetylcholinesterase (AChE) inhibitors (AChEIs) and one N-methyl D-aspartate (NMDA) receptor antagonist—memantine—have been approved for the management of cognitive symptoms of AD [12]. The gene discussed is ACHE; the disease is Alzheimer disease.